Biocon Biologics, Author at Biocon Biologics

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Global HQ

Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr

Biocon Foundation and IISc organize OCTF Conference on Artificial Intelligence in Oral Cancer

US FDA Completes Inspection at Biocon Biologics’ Facilities at Biocon Park, Bengaluru, India

Biocon Biologics Moves into New North American Headquarters in Bridgewater, New Jersey

EMA Approves Biocon Biologics’ New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites

Biocon Foundation conducts awareness session in 14 Government Schools

Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr

Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India

Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®

Agree >>

Agree >>

Agree >>